about
Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activityAnimal and human mucosal tissue models to study HIV biomedical interventions: can we predict success?In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicideDevelopment of HIV-1 rectal-specific microbicides and colonic tissue evaluationCan a topical microbicide prevent rectal HIV transmission?Trichomonas vaginalis-induced epithelial monolayer disruption and human immunodeficiency virus type 1 (HIV-1) replication: implications for the sexual transmission of HIV-1HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificitiesPerformance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediatorsTargeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles.Rectal microbicide development.Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulationsFormulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV preventionY chromosome and HIV DNA detection in vaginal swabs as biomarkers of semen and HIV exposure in womenA Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention.Effect of topical microbicides on infectious human immunodeficiency virus type 1 binding to epithelial cellsThe effect of menopause on the innate antiviral activity of cervicovaginal lavage.Vaginal Microbicide Film Combinations of Two Reverse Transcriptase Inhibitors, EFdA and CSIC, for the Prevention of HIV-1 Sexual Transmission.Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities.Cryopreservation of Human Mucosal Leukocytes.Assessing the potential of the Woman's Condom for vaginal drug deliverySoluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young Women.Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women.Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 PreventionReformulated tenofovir gel for use as a dual compartment microbicide.Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 preventionMucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial.Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir GelBroadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex VivoDistinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue.Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study.HIV-1 infection of female genital tract tissue for use in prevention studiesCervical shedding of human T cell lymphotropic virus type I is associated with cervicitisExtracts from Acacia catechu suppress HIV-1 replication by inhibiting the activities of the viral protease and Tat.A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis.Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1.
P50
Q21133918-B1DA37B6-AF03-4578-BBD6-E0C7A1CB1E8AQ26777022-4976307F-F167-46D0-A38A-DB928D405353Q28472968-61042E5B-8486-4B16-A3C8-B3C3A3A635F9Q28540761-6C8D4822-0CBE-498E-B0B4-11A14F6A4D13Q33358267-809986D3-C20A-4BC2-8CA8-C78B9B70DF7BQ33883421-8206B826-F637-44F5-9212-9E181ED5378FQ33939974-A061D592-890C-4590-95CA-3BCBABEA86D6Q33999185-20660789-F437-468E-91C3-8315BC3D7DE4Q34568549-0344F393-0249-4587-B5A8-C44CFE4F375DQ34575590-9251D17A-EE7E-448E-B662-61529786752CQ34704317-1EEF652A-ADEC-4195-A127-236663DF3567Q35002085-A5AB29D9-526F-4524-8036-D4600EF2D81FQ35136930-75511474-8384-4747-B977-999327500A88Q35571216-1CAC6967-16A0-4394-8E34-5E8D5F1754B0Q35759112-61390969-1894-42BB-B67A-62F4E649550CQ35822713-D69DE581-CA60-4CC7-9782-E08766D41E8EQ35840798-87FDE8FA-BD19-4D0E-9B5A-8E492BAE9AC7Q35901184-256EC648-CD9E-4A17-B344-7D38CD02177BQ35929032-3DBB5D48-6D19-4685-997B-7A22A01683C6Q36018776-79B0EE29-C030-4425-A1CA-999DC58D3758Q36018914-EFF32228-705A-4072-83F1-49D7BECCF8B9Q36032572-D4F92D6E-89BA-4164-A981-556C3AACD3EDQ36039442-9728C788-5A64-407F-959E-3A783E531863Q36068677-C774B7C2-69CA-405D-8625-6C8496F2862CQ36068904-3D02AA64-36E2-4994-9F37-228BFB87C3B4Q36143276-08ACE79F-D936-4AE3-AF0E-36670657B002Q36159765-A6C56A75-B6AD-475E-AF7B-F2304C092FF4Q36409617-904CADAD-EABC-4624-9F43-8AB73039DF25Q36412234-E8FEF54F-2E3C-4571-9552-D40EAB99FF55Q36446138-9DB7FD6C-F846-48E1-8B88-3BFDFC3FF60BQ36571900-89E05CD8-33CE-4911-AAD2-7EF5941440B9Q36888077-5EAC2066-C48F-48FC-AC2C-FE7B27ACD62EQ37107494-AD13C849-2405-4CFD-964B-66A8FB706B2FQ37141860-C5E9BDD2-4D90-4812-82EF-357CE8C0BFD4Q37176223-9572A974-569C-46A8-AEF8-FCACA1B4906DQ37285671-66510A06-DDC4-4AF2-83AE-1CF8533B396AQ37293488-7CC844E5-7412-42EC-B08D-3AAB23C0EA11Q37410434-BEEE5F19-8F9D-40F8-8E49-B83553CEF244Q37694939-236EF27C-CB91-4EAE-B358-CB6DF0E77CC0Q40819252-5EBA0517-F321-48E2-9EF1-DE7D14E69B8A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Charlene S Dezzutti
@ast
Charlene S Dezzutti
@en
Charlene S Dezzutti
@es
Charlene S Dezzutti
@nl
Charlene S Dezzutti
@sl
type
label
Charlene S Dezzutti
@ast
Charlene S Dezzutti
@en
Charlene S Dezzutti
@es
Charlene S Dezzutti
@nl
Charlene S Dezzutti
@sl
prefLabel
Charlene S Dezzutti
@ast
Charlene S Dezzutti
@en
Charlene S Dezzutti
@es
Charlene S Dezzutti
@nl
Charlene S Dezzutti
@sl
P106
P31
P496
0000-0001-5902-5841